Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing ?-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing ?-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The present invention relates to a new process for the preparation of ammeline and/or ammelide from melamine by a solid-to-solid reaction in an aqueous reaction mixture comprising a biocatalyst, wherein the biocatalyst comprises at least one enzyme belonging to the amidohydrolase superfamily and having aminohydrolase activity towards 1,3,5-triazine compounds. The invention further relates a product obtainable by the process according to the invention, wherein the product comprises ammeline and/or ammelide.

Abstract: The invention relates to a flame-retardant polyamide composition comprising a polyamide with a melting temperature higher than 265° C. and ammeline and/or ammelide, in which the ammeline and/or ammelide is obtainable by a biocatalytic process from melamine in an aqueous reaction mixture comprising a biocatalyst, wherein melamine is converted into ammeline and optionally further into ammelide.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing E-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The present invention relates to a new process for the preparation of ammeline and/or ammelide from melamine by a solid-to-solid reaction in an aqueous reaction mixture comprising a biocatalyst, wherein the biocatalyst comprises at least one enzyme belonging to the amidohydrolase superfamily and having aminohydrolase activity towards 1,3,5-triazine compounds. The invention further relates a product obtainable by the process according to the invention, wherein the product comprises ammeline and/or ammelide.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing ?-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing e-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The invention relates to a flame-retardant polyamide composition comprising a polyamide with a melting temperature higher than 265° C. and ammeline and/or ammelide, in which the ammeline and/or ammelide is obtainable by a biocatalytic process from melamine in an aqueous reaction mixture comprising a biocatalyst, wherein melamine is converted into ammeline and optionally further into ammelide.

Abstract: The present invention relates to a novel method for the preparation of 1,4-diaminobutane [DAB]. The method according to the present invention involves at least one biocatalytic step which comprises the biocatalytic production of at least one N-protected precursor of DAB. The present invention also relates to a method for the preparation of DAB involving at least one biocatalytic step, and comprising the steps of a) biocatalytically preparing an N-protected precursor of DAB yielding a—biocatalytic reaction mixture containing the N-protected precursor of DAB, b) recovering the N-protected precursor from the biocatalytic reaction mixture and c) converting the N-protected precursor into DAB. More in particular, the present invention relates to a method for the preparation of DAB, wherein the at least N-protected precursor of DAB is selected from the group consisting of N5-protected ornithine, N-protected DAB, and N-protected 4-aminobutyraldehyde.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing e-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing e-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.

Abstract: The invention is directed to a method for preparing 6-aminocaproic acid, comprising decarboxylating alpha-aminopimelic acid, using at least one biocatalyst comprising an enzyme having alpha-aminopimelic acid decarboxylase activity. The invention is further directed to a method for preparing caprolactam from 6-aminocaproic acid prepared by said method, to a host cell suitable for use in a method according to the invention and to a polynucleotide encoding a decarboxylase that may be used in a method according to the invention.

Abstract: The present invention relates to a method for preparing alpha-ketopimelic acid, comprising converting 2-hydroxyheptanedioic acid into alpha-ketopimelic acid, which conversion is catalysed using a biocatalyst. Further, the invention relates to a heterologous cell, comprising a nucleic acid sequence encoding an enzyme having catalytic activity in the conversion of 2-hydroxyheptanedioic acid into alpha-ketopimelic acid. Further, the invention relates to the use of a heterologous cell according to the invention in the preparation of caprolactam, diaminohexane or adipic acid.

Abstract: The present invention relates to a novel method for the preparation of 1,4-diaminobutane [DAB]. The method according to the present invention involves at least one biocatalytic step which comprises the biocatalytic production of at least one N-protected precursor of DAB. The present invention also relates to a method for the preparation of DAB involving at least one biocatalytic step, and comprising the steps of a) biocatalytically preparing an N-protected precursor of DAB yielding a—biocatalytic reaction mixture containing the N-protected precursor of DAB, b) recovering the N-protected precursor from the biocatalytic reaction mixture and c) converting the N-protected precursor into DAB. More in particular, the present invention relates to a method for the preparation of DAB, wherein the at least N-protected precursor of DAB is selected from the group consisting of N5-protected ornithine, N-protected DAB, and N-protected 4-aminobutyraldehyde.

Abstract: The invention relates to a method for preparing alpha-ketopimelic acid, comprising converting alpha-ketoglutaric acid into alpha-ketoadipic acid and converting alpha-ketoadipic acid into alpha-ketopimelic acid, wherein at least one of these conversions is carried out using a heterologous biocatalyst. The invention further relates to a heterologous cell, comprising one or more heterologous nucleic acid sequences encoding one or more heterologous enzymes capable of catalysing at least one reaction step in the preparation of alpha-ketopimelic acid from alpha-ketoglutaric acid.

Abstract: The invention relates to a method for preparing adipic acid, comprising converting alpha-ketoglutaric acid (AKG) into alpha-ketoadipic acid (AKA), converting alpha-ketoadipic acid into alpha-ketopimelic acid (AKP), converting alpha-ketopimelic acid into 5-formylpentanoic acid (5-FVA), and converting 5-formylpentanoic acid into adipic acid, wherein at least one of these conversions is carried out using a heterologous biocatalyst.The invention further relates to a heterologous cell, comprising one or more heterologous nucleic acid sequences encoding one or more heterologous enzymes capable of catalysing at least one reaction step in said method.

Abstract: The invention relates to a method for preparing ?-caprolactam comprising deacylating N-acyl-6-aminocaproic acid and forming ?-caprolactam. The deacylation may be carried out chemically or biocatalytically. The invention further relates to a host cell, comprising a recombinant vector comprising a nucleic acid sequence encoding an enzyme capable of catalysing the formation of 6-aminocaproic acid from N-acyl-6-aminocaproic acid.

Abstract: The invention relates to a method for preparing ?-caprolactam comprising reducing the carbon-carbon double bond of (Z)-6,7-dihydro-1H-azepin-2(5H)-one, wherein the reduction is catalysed by a biocatalyst. The invention further relates to a novel host cell comprising a biocatalyst capable of catalysing said reduction and to a novel polynucleotide encoding a biocatalyst capable of catalysing said reduction.

Abstract: The invention relates to a method for preparing 6-aminocaproic acid (hereinafter also referred to as ‘6-ACA’) using a biocatalyst. The invention further relates to a method for preparing e-caprolactam (hereafter referred to as ‘caprolactam’) by cyclising such 6-ACA. The invention further relates to a host cell, a micro-organism, or a polynucleotide which may be used in the preparation of 6-ACA or caprolactam.